Suboxone
Phase 3Small molecule
Merck & Co.Suboxone is one of 42 small molecule programs targeting Hepatitis C. It is currently in Phase 3.
3
Indications
10
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Sovaldi
GileadApproved
Actos
TakedaApproved
Selzentry
GSKApproved
Afinitor
NovartisApproved
Neoral
NovartisApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Prograf
VVeloxis Pharmaceuticals
Approved
Trental
VValidus Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Remeron
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Opioid Use Disorder1 trial
Opioid1 trial
Houston Emergency Opioid Engagement System
Enrolling by invitation·TThe University of Texas Health Science Center, Houston·Phase 4·NCT03396276·3,000 enrolled
Telemedicine1 trial
Providing Suboxone and PrEP Using Telemedicine
Completed·—·N/A·NCT04521920·17 enrolled
5 more indications
Opiate Dependence1 trial
Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Completed·—·Phase 3·NCT02696096·21 enrolled
Hepatitis C1 trial
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
Completed·—·N/A·NCT05108935·17 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Suboxone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company